Novartis AG ($NVS) Stock Forecast: Down 1.7% Today

What is Novartis AG?

Novartis (NVS) is a pharmaceutical company recognized for its innovative treatments across various therapeutic areas. Today, the stock saw a significant downwards trend in the market.

Why is Novartis AG going down?

NVS stock is down 1.7% on Apr 16, 2024 17:37

• Positive data regarding Fabhalta for a rare kidney disease may have been eclipsed by market concerns or uncertainties.
• Despite encouraging results from a phase III study, investors possibly reacted unfavorably to other influencing factors affecting Novartis.
• The recent acquisition of Alpine Immune Sciences by Vertex Pharmaceuticals might have diverted investor attention from Novartis, leading to the bearish market movement.
• The growing market presence of a Humira biosimilar, indirectly connected to Novartis, could have impacted investor sentiment towards the pharmaceutical industry as a whole, playing a role in NVS's decline.

NVS Price Chart

NVS News

Novartis ( NVS ) Presents Positive Data on Rare Kidney Disease Drug

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

https://www.zacks.com/stock/news/2256142/novartis-nvs-presents-positive-data-on-rare-kidney-disease-drug

Novartis'' Fabhalta Demonstrates Significant Proteinuria Reduction In IgA Nephropathy Patients

BASEL (dpa-AFX) - Novartis (NVS) presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta (iptacopan), an investigational Factor B inhibitor of the …

https://www.finanznachrichten.de/nachrichten-2024-04/61953647-novartis-fabhalta-demonstrates-significant-proteinuria-reduction-in-iga-nephropathy-patients-020.htm

Thanks to CVS, a Humira biosimilar is grabbing huge market share

The number of new prescriptions for biosimilar versions of the Humira rheumatoid arthritis treatment increased by 36% in the first week of April, up from 5%, due to CVS Health’s expanding reach in the prescription drug market. This surge was led by the biosimilar Hyrimoz, manufactured by Sandoz, a Novartis unit, and marketed with CVS’s…

https://dataemia.com/2024/04/thanks-to-cvs-a-humira-biosimilar-is-grabbing-huge-market-share/

Novartis Pharma AG: New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare …

https://www.finanznachrichten.de/nachrichten-2024-04/61951405-novartis-pharma-ag-new-novartis-fabhalta-iptacopan-data-show-clinically-meaningful-and-statistically-significant-proteinuria-reduction-of-38-3-ve-399.htm

Vertex Pharma to acquire Alpine Immune Sciences for $4.9 billion to strengthen scientific innovation

Vertex Pharmaceuticals and Alpine Immune Sciences, Inc … According to a report by Pharmabiz , the transaction was unanimously approved … of its RSV vaccine Sun Pharma halts trial of its … Natco Pharma recall drugs in US market due to manufacturing issues Novartis …

https://www.financialexpress.com/healthcare/pharma-healthcare/vertex-pharma-to-acquire-alpine-immune-sciences-for-4-9-billion-to-strengthen-scientific-innovation/3454641/

Trending Today

Fantom ($FTM) Crypto Forecast: Down 5.6% Today

Uniswap ($UNI) Crypto Forecast: Down 5.6% Today

ApeCoin ($APE) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.2% Today

Injective ($INJ) Crypto Forecast: Up 5.3% Today

Internet Computer ($ICP) Crypto Forecast: Up 6.0% Today

Render ($RENDER) Crypto Forecast: Up 5.0% Today

POL (Polygon) ($POL) Crypto Forecast: Down 5.2% Today

Celestia ($TIA) Crypto Forecast: Up 9.3% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.3% Today

Novartis AG Price History

16.03.2024 - NVS Stock was down 1.7%

• Positive data regarding Fabhalta for a rare kidney disease may have been eclipsed by market concerns or uncertainties.
• Despite encouraging results from a phase III study, investors possibly reacted unfavorably to other influencing factors affecting Novartis.
• The recent acquisition of Alpine Immune Sciences by Vertex Pharmaceuticals might have diverted investor attention from Novartis, leading to the bearish market movement.
• The growing market presence of a Humira biosimilar, indirectly connected to Novartis, could have impacted investor sentiment towards the pharmaceutical industry as a whole, playing a role in NVS's decline.